Effect on HPV vaccination in Japan resulting from news report of adverse events and suspension of governmental recommendation for HPV vaccination

Morimoto, Akira; Ueda, Yutaka; Egawa-Takata, Tomomi; Yagi, Akira; Terai, Yoshito; Ohmichi, Masahide; Ichimura, Tsuyoshi; Sumi, Toshiyuki; Murata, Hiromi; Kanzaki, Hideharu; Nakai, Hidekatsu; Mandai, Masaki; Yoshino, Kiyoshi; Fujita, Masami; Kimura, Tadashi; Saito, Junko; Sobue, Tomotaka; Nishikawa, Nobumichi; Sekiguchi, Masayuki; Enomoto, Takayuki; Horikoshi, Yorihiko; Такаги, Таичиро

doi:10.1007/s10147-014-0723-1

Cited by 53 publications

(39 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In June 2013, the Japanese government temporarily suspended the active promotion of the HPV vaccination program because of adverse reactions, and this has not yet resumed [9]. Morimoto et al reported that this suspension reduced the coverage of the first dose of the HPV vaccination by 97% in June 2013, compared with the same month in is officially published) [10]. These situations in Japan might result in increasing CC mortality rate among young women.…”

Section: Introductionmentioning

confidence: 97%

Increasing trends in cervical cancer mortality among young Japanese women below the age of 50 years: An analysis using the kanagawa population-based cancer registry, 1975–2012

Motoki

Mizushima

Taguri

et al. 2015

Cancer Epidemiology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 97%

Increasing trends in cervical cancer mortality among young Japanese women below the age of 50 years: An analysis using the kanagawa population-based cancer registry, 1975–2012

Motoki

Mizushima

Taguri

et al. 2015

Cancer Epidemiology

View full text Add to dashboard Cite

“…Since April 2013, the bivalent and quadrivalent vaccines (Cervarix and Gardasil) have been included in the national immunization program. However, due to potential adverse effects of HPV vaccination, such as chronic pain, the proactive recommendation for vaccination was suspended in June 2013 (Morimoto et al 2014;Ueda et al 2015;Hanley et al 2015). The Vaccine Adverse Review Committee of the Japanese Ministry of Health investigated adverse events in about 8,898,000 injections from 2010 to 2013.…”

Section: Introductionmentioning

confidence: 99%

Beneficial Effects of Human Papillomavirus Vaccine for Prevention of Cervical Abnormalities in Miyagi, Japan

Ozawa¹,

Itō

Tase

et al. 2016

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Prevention of cervical cancer has been unsuccessful in Japan because of low rates of cancer screening and vaccination. The Vaccine Adverse Review Committee of the Japanese Government investigated 2,475 adverse events and reported 617 (6.9/100,000) severe cases and 176 (2.0/100,000) cases with chronic pain. The proactive recommendation for human papillomavirus (HPV) vaccination has been suspended since June 2013. In this study, we examined vaccination rate and incidence of abnormal cervical cytology in women aged 20 to 24 years attending cancer screening in Miyagi. Among the 3,272 women who underwent a health check in the fiscal year 2014 (April 2014-March 2015), 332 (10.2%) received a HPV vaccination. The HPV vaccination rates were 42.3%, 10%, 17.5%, 3.8% and 4.0% in women aged 20, 21, 22, 23 and 24 years, respectively. The rates of atypical squamous cells of undetermined significance (ASC-US) or worse were 2.41% (8/332) in women with HPV vaccination and 5.03% (148/2,940) in those without HPV vaccination, indicating a significant decrease in vaccinated women (p = 0.03). ASC-US cases were referred to HPV DNA tests. In addition, the rates of high grade squamous intraepithelial lesion (HSIL) or worse were 0.30% (1/332) in women with HPV vaccination and 0.82% (24/2,940) in those without HPV vaccination, showing the marginal decrease in women who were vaccinated (p = 0.3). Thus, this study indicates that HPV vaccination is associated with a reduction in the incidence of cervical abnormalities, suggesting a need for scientific discussion of reinstatement of proactive recommendation for HPV vaccine in Japan.

show abstract

“…4,14 In early spring of the same year, media coverage about these adverse events was frequent and the vaccination rate for HPV decreased dramatically. 15 Our results might reflect mothers' wishes to avoid risk even if the risk of an adverse event is slight. Therefore, if new combination vaccines are introduced in Japan, the risk of adverse events is an important factor for mothers.…”

Section: Discussionmentioning

confidence: 74%

Mothers' preferences regarding new combination vaccines for their children in Japan, 2014

Shono

Kondo

2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

A number of new vaccines to prevent childhood diseases have been introduced globally over the last few decades. Only four combination vaccines are currently available in Japan, DTaP/sIPV, DTaP, DT, and MR, leading to complex infant vaccine scheduling. This study aims to investigate mothers' preferences with respect to combination vaccines for their children, should new combination vaccines become available that have not yet been launched in Japan or that will be developed in the future. We conducted a webbased, cross-sectional survey of 1,243 mothers who had at least one child between 2 months and 3 y of age. Mothers were recruited from an online survey panel of registered users. Their preferences were elicited using discrete choice experiments, the analyzed main effects model, and interactions using a mixed logit model. Mothers showed a preference for vaccines that prevented multiple diseases, had fewer injections per doctor visit, lower price, and lower risk of adverse events. Respondents valued a reduced risk of adverse events the most among all attributes in this study. The estimated monetary value of the willingness to pay for a 1% reduction in the risk of adverse events was < 92,557 ($ 907). Therefore, if new combination vaccines are introduced, the risk of adverse events after vaccination is an especially important factor for mothers. While the safety of the vaccines themselves is required, health professionals should also inform mothers about the benefits and risks of vaccination, to allay mothers' concerns about vaccine safety.

show abstract

Effect on HPV vaccination in Japan resulting from news report of adverse events and suspension of governmental recommendation for HPV vaccination

Abstract: Our results should help in understanding the need for a strong promotion of vaccine usage and cancer screening after future retraction of the recommendation suspension. This may apply to other countries with an unsatisfactory rate of HPV vaccination due to fears of adverse vaccine events.

Cited by 53 publications

References 22 publications

Increasing trends in cervical cancer mortality among young Japanese women below the age of 50 years: An analysis using the kanagawa population-based cancer registry, 1975–2012

Increasing trends in cervical cancer mortality among young Japanese women below the age of 50 years: An analysis using the kanagawa population-based cancer registry, 1975–2012

Beneficial Effects of Human Papillomavirus Vaccine for Prevention of Cervical Abnormalities in Miyagi, Japan

Mothers' preferences regarding new combination vaccines for their children in Japan, 2014

Contact Info

Product

Resources

About